ES2696074T3 - Tratamiento del cáncer de mama - Google Patents

Tratamiento del cáncer de mama Download PDF

Info

Publication number
ES2696074T3
ES2696074T3 ES12846720T ES12846720T ES2696074T3 ES 2696074 T3 ES2696074 T3 ES 2696074T3 ES 12846720 T ES12846720 T ES 12846720T ES 12846720 T ES12846720 T ES 12846720T ES 2696074 T3 ES2696074 T3 ES 2696074T3
Authority
ES
Spain
Prior art keywords
trip trip
tio
tra
breast cancer
amen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12846720T
Other languages
English (en)
Spanish (es)
Inventor
Andrew A Protter
Jennifer Richer
Dawn Cochrane
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivation Prostate Therapeutics LLC
University of Colorado System
University of Colorado Colorado Springs
Original Assignee
Medivation Prostate Therapeutics LLC
University of Colorado System
University of Colorado Colorado Springs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2696074(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics LLC, University of Colorado System, University of Colorado Colorado Springs filed Critical Medivation Prostate Therapeutics LLC
Application granted granted Critical
Publication of ES2696074T3 publication Critical patent/ES2696074T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12846720T 2011-07-29 2012-07-27 Tratamiento del cáncer de mama Active ES2696074T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
ES2696074T3 true ES2696074T3 (es) 2019-01-14

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12846720T Active ES2696074T3 (es) 2011-07-29 2012-07-27 Tratamiento del cáncer de mama

Country Status (18)

Country Link
US (4) US9517229B2 (OSRAM)
EP (4) EP3610731A1 (OSRAM)
JP (2) JP6158180B2 (OSRAM)
KR (1) KR101923250B1 (OSRAM)
CN (1) CN103997894B (OSRAM)
BR (1) BR112014002200A2 (OSRAM)
CA (1) CA2843417C (OSRAM)
CY (1) CY1121038T1 (OSRAM)
DK (1) DK2739153T3 (OSRAM)
EA (1) EA028452B1 (OSRAM)
ES (1) ES2696074T3 (OSRAM)
HU (1) HUE040524T2 (OSRAM)
MX (1) MX359664B (OSRAM)
PH (1) PH12014500248B1 (OSRAM)
PL (1) PL2739153T3 (OSRAM)
PT (1) PT2739153T (OSRAM)
SI (1) SI2739153T1 (OSRAM)
WO (1) WO2013066440A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX359664B (es) * 2011-07-29 2018-10-05 Univ Colorado Regents Tratamiento de cáncer de mama.
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
UA115805C2 (uk) * 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
CA2929715A1 (en) * 2013-11-07 2015-05-14 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie2 kinase useful in the treatment of cancer
WO2015184145A1 (en) * 2014-05-28 2015-12-03 Eisai R&D Management Co., Ltd. Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
SG11201704425TA (en) * 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
CN107530291A (zh) 2015-03-03 2018-01-02 奎尔波特股份有限公司 双重负载的脂质体药物制剂
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
UA129105C2 (uk) 2017-10-16 2025-01-15 Арагон Фармасьютикалз, Інк. Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
KR20230058410A (ko) * 2020-08-03 2023-05-03 온코사이트 코포레이션 종양의 분류 및 반응성 예측
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2007245022A1 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
KR101332889B1 (ko) * 2005-05-13 2013-11-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
WO2007061876A2 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
EP4385574A3 (en) 2006-03-27 2024-10-02 The Regents of the University of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
TWI557111B (zh) 2007-10-26 2016-11-11 加州大學董事會 二芳基乙內醯脲類化合物
US8450290B2 (en) 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) * 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
HRP20140140T1 (en) 2008-05-30 2014-05-23 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
MX2011008858A (es) 2009-02-24 2012-01-27 Medivation Prostate Therapeutics Inc Compuestos de diarilhidantoina y diariltiohidantoina especificos.
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
WO2011022316A1 (en) 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
EP2485804A4 (en) * 2009-10-07 2015-07-29 Medivation Technologies Inc SUBSTITUTED PHENYLCARBAMOYL ALKYLAMINOAREN COMPOUNDS AND N, N'-BIS-ARYL UREA COMPOUNDS
WO2012125828A2 (en) 2011-03-15 2012-09-20 The University Of North Carolina At Chapell Hill Methods of treating breast cancer with anthracycline therapy
MX359664B (es) * 2011-07-29 2018-10-05 Univ Colorado Regents Tratamiento de cáncer de mama.
EP2785873A4 (en) 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
ES2696202T3 (es) 2012-08-23 2019-01-14 Univ Colorado Regents Método para determinar el tratamiento de cáncer de mama
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
SG11201704425TA (en) 2014-12-12 2017-06-29 Medivation Prostate Therapeutics Inc Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer

Also Published As

Publication number Publication date
SI2739153T1 (sl) 2018-12-31
BR112014002200A2 (pt) 2017-03-07
HK1201413A1 (en) 2015-09-04
CN103997894A (zh) 2014-08-20
JP2014524934A (ja) 2014-09-25
CN103997894B (zh) 2016-08-24
US20210069154A1 (en) 2021-03-11
CA2843417C (en) 2018-08-21
HK1198867A1 (en) 2015-06-19
EA028452B1 (ru) 2017-11-30
EP2739153B1 (en) 2018-08-22
JP6158180B2 (ja) 2017-07-05
US20140296312A1 (en) 2014-10-02
DK2739153T3 (en) 2018-12-03
US10111861B2 (en) 2018-10-30
WO2013066440A9 (en) 2013-07-18
PH12014500248A1 (en) 2014-03-17
JP2017141269A (ja) 2017-08-17
HUE040524T2 (hu) 2019-03-28
EP3610731A1 (en) 2020-02-19
PT2739153T (pt) 2018-11-28
PH12014500248B1 (en) 2018-08-31
PL2739153T3 (pl) 2019-04-30
EP2739153A4 (en) 2015-03-11
KR101923250B1 (ko) 2018-11-28
US20190262315A1 (en) 2019-08-29
MX359664B (es) 2018-10-05
US9517229B2 (en) 2016-12-13
CA2843417A1 (en) 2013-05-10
EP3791724A1 (en) 2021-03-17
EP3430907A1 (en) 2019-01-23
CY1121038T1 (el) 2019-12-11
EP2739153A1 (en) 2014-06-11
MX2014001218A (es) 2014-08-22
US20170087132A1 (en) 2017-03-30
KR20140107174A (ko) 2014-09-04
WO2013066440A1 (en) 2013-05-10
EA201400178A1 (ru) 2014-11-28

Similar Documents

Publication Publication Date Title
ES2696074T3 (es) Tratamiento del cáncer de mama
Costantini et al. Controlling pain in the post-operative setting
JP2019536805A5 (OSRAM)
Sankar et al. Oral complications from oropharyngeal cancer therapy
RU2018142394A (ru) Композиции и способы для лечения нейтропении
Baldari et al. Management of metastatic castration-resistant prostate cancer: a focus on radium-223: opinions and suggestions from an expert multidisciplinary panel
Chakraborty et al. Advances in radionuclides and radiolabelled peptides for cancer therapeutics
Li et al. First deciphering of large pterosaur footprints and their trackmaker in the Junggar Basin, China
Machida et al. Aldosterone-, corticosterone-and cortisol-secreting adrenocortical carcinoma in a dog: case report
JP2005082523A (ja) 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬
BR112014027576B1 (pt) soluções de oligoelementos
Smith et al. A new species of Kryptobaatar (Multituberculata): the first Late Cretaceous mammal from Inner Mongolia (PR China)
Muhamedagić et al. Sex determination of the Bosnian-Herzegovinian population based on odontometric characteristics of permanent lower canines
Eismann et al. Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors
Cross et al. New immigrating racial and ethnic populations and" trends impacts" on state vocational rehabilitation agencies
Herman Progress and dilemma of contemporary clinical pharmacology.
Mhingo Australian vaccine could put stop to malaria
Pangrazio et al. Safety of International Professional Sports Competitions During The COVID-19 Pandemic: The Association Football Experience
Dumontet et al. P-479 Expression of class III beta tubulin is predictive of patientoutcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
Iwanaga et al. A novel method for visualization of the inferior alveolar nerve for clinical and educational purposes
Elmekaty et al. 38 Excellence in medication reconciliation during COVID-19 pandemic
Gremaud A likelihood ratio approach to identification in forensic odontology
Domine et al. P-477 Biweekly carboplatin and gemcitabine for untreated advancednon-small cell lung cancer (NSCLC). A multicenter phase II trial
ANG 7 Advances in the Treatment of Head and Neck Cancer
Carpenter et al. Comment on Allosaurus Marsh, 1877 (Dinosauria, Theropoda): proposed conservation of usage by designation of a neotype for its type species Allosaurus fragilis Marsh, 1877 (Case 3506)